ADT and Cardiovascular Risk: Insights from the REVELUTION Study
The REVELUTION trial provides mechanistic insight into ADT-related cardiovascular risk through plaque progression.
Read More
Select Page
Sagar A. Patel, MD, is a board-certified Radiation Oncologist and the Director of Brachytherapy in the Department of Radiation Oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He is also an Associate Professor in the Departments of Radiation Oncology and Urology at the Emory University School of Medicine. He specializes in the treatment of genitourinary cancers, including prostate, bladder and kidney cancer. He received a Master of Science in Clinical Research at Emory University and completed his medical degree at Harvard Medical School. He also completed residency training at the Harvard Radiation Oncology Program and fellowship training in Prostate Brachytherapy at UCLA.
Dr. Patel's primary research interest is predicting and mitigating hormone therapy toxicity in prostate cancer patients. He is also interested in comparative outcomes between advanced techniques for prostate cancer, including brachytherapy, SBRT, and proton therapy. He is Principal Investigator for randomized clinical trials assessing novel hormone therapy drugs in combination with radiation therapy for prostate cancer.
Sagar A. Patel, MD and E. David Crawford, MD | Apr 2026
The REVELUTION trial provides mechanistic insight into ADT-related cardiovascular risk through plaque progression.
Read More